Earle F. Burgess

Earle F. Burgess

Auto-generated profile, based on publicly available information

Earle F. Burgess

Atrium Health Wake Forest Baptist Comprehensive Cancer Center Charlotte North Carolina USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
YLYohann Loriot
Yohann Loriot
ANAndrea Necchi
Andrea Necchi
SPSe Hoon Park
Se Hoon Park
JGJesus Garcia-Donas
Jesus Garcia-Donas
RHRobert Huddart
Robert Huddart
ASArlene O. Siefker-Radtke
Arlene O. Siefker-Radtke
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common in urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity in preclinical models and in a phase 1 study involving patients with FGFR alterations.

1 September 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
POPeter H. O'DOnnell
Peter H. O'DOnnell
MMMatthew I Milowsky
Matthew I Milowsky
DPDaniel P. Petrylak
Daniel P. Petrylak
Christopher HoimesChristopher Hoimes
Christopher Hoimes
TFThomas William Flaig
Thomas William Flaig
JRJonathan E. Rosenberg
Jonathan E. Rosenberg
PURPOSE: Patients with locally advanced or metastatic urothelial cancer (la/mUC) who are ineligible for cisplatin-based therapy have limited first-line (1L) treatment options and significant need for improved therapies. Enfortumab vedotin (EV) and pembrolizumab (Pembro) individually have shown a survival benefit in urothelial cancer in second-line + la/mUC settings. Here, we present data from the pivotal trial of EV plus Pembro (EV + Pembro) in the 1L setting. PATIENTS AND METHODS: In Cohort K of the EV-103 phase Ib/II study, cisplatin-ineligible patients with previously untreated la/mUC were randomly assigned 1:1 to receive EV as monotherapy or in combination with Pembro. The primary end point was confirmed objective response rate (cORR) per blinded independent central review. Secondary end points included duration of response (DOR) and safety. There were no formal statistical comparisons between treatment arms. RESULTS: The cORR was 64.5% (95% CI, 52.7 to 75.1) and 45.2% (95% CI, 33.5 to 57.3) for patients treated with EV + Pembro (N = 76) and EV monotherapy (N = 73), respectively. The median DOR was not reached for the combination and was 13.2 months for monotherapy; 65.4% and 56.3% of patients who responded to the combination and monotherapy, respectively, maintained a response at 12 months. The most common grade 3 or higher treatment-related adverse events (TRAEs) in patients treated with the combination were maculopapular rash (17.1%), fatigue (9.2%), and neutropenia (9.2%). EV TRAEs of special interest (any grade) in the combination arm included skin reactions (67.1%) and peripheral neuropathy (60.5%). CONCLUSION: EV + Pembro showed a high cORR with durable responses as 1L treatment in cisplatin-ineligible patients with la/mUC. Patients who received EV monotherapy had a response and safety profile consistent with previous studies. Adverse events for EV + Pembro were manageable, with no new safety signals observed.

1 September 2015 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EKEdward S. Kim
Edward S. Kim
DBDavid Bernstein
David Bernstein
SHSusan G. Hilsenbeck
Susan G. Hilsenbeck
CCChristine H. Chung
Christine H. Chung
ADAdam P. Dicker
Adam P. Dicker
RSRichard L. Schilsky
Richard L. Schilsky
As more clinical trials of molecularly targeted agents evolve, the number of eligibility criteria seems to be increasing. The importance and utility of eligibility criteria must be considered in the context of the fundamental goal of a clinical trial: to understand the risks and benefits of a treatment in the intended-use patient population. Although eligibility criteria are necessary to define the population under study and conduct trials safely, excessive requirements may severely restrict the population available for study, and often, this population is not reflective of the general population for which the drug would be prescribed. The American Society of Clinical Oncology Cancer Research Committee, which comprises academic faculty, industry representatives, and patient advocates, evaluated this issue. Evaluation results were mixed. Most physicians agreed that excessive eligibility criterias slow study enrollment rates and prolong the duration of enrollment; however, this hypothesis was difficult to validate with the data examined. We propose the organization of a public workshop, with input from regulatory bodies and key stakeholders, with the goal of developing an algorithmic approach to determining eligibility criteria for individual study protocols, which may help guide future investigators and companies in streamlining eligibility criteria in the era of molecularly driven therapy.

2 September 2008 in Proteomics – Clinical Applications
Verified
Journal Article
Closed access
PDF file
EBEarle F. Burgess
Earle F. Burgess
AHAmy‐Joan L. Ham
Amy‐Joan L. Ham
DTDavid Tabb
David Tabb
DBDean Billheimer
Dean Billheimer
BRBruce J. Roth
Bruce J. Roth
JPJennifer A. Pietenpol
Jennifer A. Pietenpol

30 May 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
SGShuchi Gulati
Shuchi Gulati
PBPedro Barata
Pedro Barata
AEAndrew Elliott
Andrew Elliott
MBMehmet Bilen
Mehmet Bilen
EBEarle F. Burgess
Earle F. Burgess
RMRana R. McKay
Rana R. McKay
BACKGROUND: Metastases are the hallmark of lethal cancer, though underlying mechanisms that drive metastatic spread to specific organs remain poorly understood. Renal cell carcinoma (RCC) is known to have distinct sites of metastases, with lung, bone, liver, and lymph nodes being more common than brain, gastrointestinal tract, and endocrine glands. Previous studies have shown varying clinical behavior and prognosis associated with the site of metastatic spread; however, little is known about the molecular underpinnings that contribute to the differential outcomes observed by the site of metastasis. METHODS: We analyzed primary renal tumors and tumors derived from metastatic sites to comprehensively characterize genomic and transcriptomic features of tumor cells as well as to evaluate the tumor microenvironment at both sites. RESULTS: We included a total of 657 tumor samples (340 from the primary site [kidney] and 317 from various sites of metastasis). We show distinct genomic alterations, transcriptomic signatures, and immune and stromal tumor microenvironments across metastatic sites in a large cohort of patients with RCC. CONCLUSION: We demonstrate significant heterogeneity among primary tumors and metastatic sites and elucidate the complex interplay between tumor cells and the extrinsic tumor microenvironment that is vital for developing effective anticancer therapies.

1 May 2019 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
EBEarle F. Burgess
Earle F. Burgess
CLChad Livasy
Chad Livasy
AHAaron Hartman
Aaron Hartman
MRMyra M. Robinson
Myra M. Robinson
JSJames Symanowski
James Symanowski
DRDerek Raghavan
Derek Raghavan